Paolo Tarantino: We cure breast cancer every day better
Paolo Tarantino shared a post on LinkedIn:
“The latest EBCTCG meta-analysis of over 150.000 patients shows a major decline in recurrence rates from breast cancer over two decades (1990-2010).
Of note, an impressive number of new approvals have further improved outcomes for this disease since 2010: dual HER2 blockade, T-DM1, neratinib, olaparib, adjuvant abemaciclib and ribociclib (just few weeks ago!).
We cure breast cancer every day better.
Thanks to MedPage Today for highlighting our editorial in The Lancet.”
More posts featuring Paolo Tarantino.
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.
His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023